Pfizer (PFE) shares declined 30 percent from Oct. 11, 2021, to Oct. 19, 2026, while the S&P 500 advanced 76.3 percent—leaving the stock 106.3 percentage points behind on price performance alone.
Dividend reinvestment narrowed that gap. Pfizer's 21.2 percentage points of cumulative dividend contributions lifted the stock's five-year total return to a loss of 8.8 percent. But even with dividends included, Pfizer lagged the market's 88.1 percent total return by 96.9 percentage points.
The math reveals the core problem: Pfizer's dividend yield of 5.8 percent, nearly twice the S&P 500's 11.7 percentage points of cumulative payouts, recovered only about nine points of the initial 106-point price decline. Income alone cannot compensate for persistent capital destruction.
The stock's recent trajectory offers limited relief. Over the past 12 months ending Oct. 19, Pfizer gained 21.5 percent on price, yielding a 30 percent total return with dividends—outpacing the S&P 500's 17 percent return. That one-year rebound, however, does not erase the five-year damage.
Pfizer's dividend is supported by its Biopharma segment, which generated 97.8 percent of total revenue in fiscal 2025. Management reiterated its commitment to maintaining and growing the payout during the Aug. 4, 2026, earnings call.
For income-focused investors, the verdict is clear: Pfizer's high yield has been insufficient to offset years of stock underperformance. Pfizer is scheduled to report fourth-quarter earnings on or around Nov. 3, 2026.
